Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis.

Callera GE, Antunes TT, Correa JW, Moorman D, Gutsol A, He Y, Cat AN, Briones AM, Montezano AC, Burns KD, Touyz RM.

Biosci Rep. 2016 Oct 27;36(5). pii: e00398.

2.

Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.

Feng YH, Fu P.

Chin Med J (Engl). 2016 Jan 5;129(1):81-7. doi: 10.4103/0366-6999.172599. Review.

3.

Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function.

Esteras R, Perez-Gomez MV, Rodriguez-Osorio L, Ortiz A, Fernandez-Fernandez B.

Ther Adv Drug Saf. 2015 Aug;6(4):166-76. doi: 10.1177/2042098615589905. Review.

4.

The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease.

Wasser WG, Gil A, Skorecki KL.

Rambam Maimonides Med J. 2015 Jul 30;6(3). doi: 10.5041/RMMJ.10214.

5.

Angiotensin II receptor blockers improve peripheral endothelial function: a meta-analysis of randomized controlled trials.

Li S, Wu Y, Yu G, Xia Q, Xu Y.

PLoS One. 2014 Mar 3;9(3):e90217. doi: 10.1371/journal.pone.0090217.

6.
7.

Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system.

Viazzi F, Leoncini G, Pontremoli R.

High Blood Press Cardiovasc Prev. 2013 Dec;20(4):273-82. doi: 10.1007/s40292-013-0027-y. Review.

8.

Direct Renin inhibitor: aliskiren in chronic kidney disease.

Morishita Y, Kusano E.

Nephrourol Mon. 2013 Winter;5(1):668-72. doi: 10.5812/numonthly.3679.

9.

TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats.

Mohanan A, Gupta R, Dubey A, Jagtap V, Mandhare A, Gupta RC, Chauthaiwale V, Dutt C.

Int J Hypertens. 2011;2011:751513. doi: 10.4061/2011/751513.

10.

Cardio classics revisited--focus on the role of candesartan.

De Rosa ML.

Vasc Health Risk Manag. 2010 Nov 23;6:1047-63. doi: 10.2147/VHRM.S9433. Review.

11.

Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.

Pichler RH, de Boer IH.

Curr Diab Rep. 2010 Aug;10(4):297-305. doi: 10.1007/s11892-010-0126-2. Review.

12.

Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan.

Kiya Y, Miura S, Fujino M, Imaizumi S, Karnik SS, Saku K.

Clin Exp Hypertens. 2010 Jan;32(2):129-36. doi: 10.3109/10641960903254430.

13.

Endothelin receptor antagonists in proteinuric renal disease: every rose has its thorn.

Ritz E, Wenzel R.

J Am Soc Nephrol. 2010 Mar;21(3):392-4. doi: 10.1681/ASN.2010010047. No abstract available.

14.

Angiotensin blockade to reduce microvascular damage in diabetes mellitus.

Schmieder RE, Martin S, Lang GE, Bramlage P, Böhm M.

Dtsch Arztebl Int. 2009 Aug;106(34-35):556-62. doi: 10.3238/arztebl.2009.0556. Review.

15.

Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review.

Bramlage P, Hasford J.

Cardiovasc Diabetol. 2009 Mar 27;8:18. doi: 10.1186/1475-2840-8-18. Review.

16.

Supramaximal dose of candesartan in proteinuric renal disease.

Burgess E, Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S; SMART (Supra Maximal Atacand Renal Trial) Investigators..

J Am Soc Nephrol. 2009 Apr;20(4):893-900. doi: 10.1681/ASN.2008040416.

17.

Therapeutic strategies to slow chronic kidney disease progression.

Wühl E, Schaefer F.

Pediatr Nephrol. 2008 May;23(5):705-16. doi: 10.1007/s00467-008-0789-y. Review.

18.

Improving outcomes in diabetes and chronic kidney disease: the basis for Canadian guidelines.

McFarlane PA, Tobe SW, Culleton B.

Can J Cardiol. 2007 May 15;23(7):585-90. Review.

Supplemental Content

Support Center